Thursday, December 6, 2007

Remoxy phase III trials meet endpoint

Durrect (DRRX 6.11 halted), less-addictive pain killer met it's endpoint. (It's in a gel-you can't snort it, and alcohol cuts it's potency.) The derivative play on DRRX is Pain Therapeutics (PTIE 10.19), who licensed the drug to King Pharmaceuticals. What is Wall Street's estimates for this drug?

Start with the $634 million fine Perdue Pharmacy paid for OxyContin.

No comments: